{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"49"},{"groupId":"OG001","spread":"0.7","value":"48"},{"groupId":"OG002","spread":"0.8","value":"48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"228"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"50"},{"groupId":"OG001","spread":"0.8","value":"51"},{"groupId":"OG002","spread":"0.8","value":"50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"166"},{"groupId":"OG002","value":"176"}],"units":"Participants"}],"title":"1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"50"},{"groupId":"OG001","spread":"0.8","value":"50"},{"groupId":"OG002","spread":"1.0","value":"50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"124"}],"units":"Participants"}],"title":"2 Years"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"51"},{"groupId":"OG001","spread":"1.1","value":"50"},{"groupId":"OG002","spread":"1.0","value":"51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"95"}],"units":"Participants"}],"title":"3 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"254"},{"groupId":"OG002","value":"257"}],"units":"Participants"}],"description":"The Medical Outcome Study (MOS) SF-36 Mental Component Summary is a subscale of the SF-36 intended to measure mental well-being. It is scored on a scale of 0-100, with higher scores indicating higher levels of well-being.","dispersionType":"Standard Deviation","groups":[{"description":"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG000","title":"Tandem Auto Transplant"},{"description":"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance\n\nlenalidomide, bortezomib and dexamethasone: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG001","title":"RVD Consolidation"},{"description":"Initial autologous transplant followed by lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG002","title":"Lenalidomide Maintenance"}],"paramType":"MEAN","populationDescription":"Outcomes are analyzed from participants that were alive, progression-free, and completed assessments.","reportingStatus":"POSTED","timeFrame":"Up to 3 years post-randomization","title":"MOS SF-36 Mental Component Summary","type":"SECONDARY","unitOfMeasure":"score on a scale"}